Jinhe Biotechnology Co Ltd (002688) — Working Capital to Net Assets Ratio
Jinhe Biotechnology Co Ltd (002688) has a Working Capital to Net Assets ratio of -4.7% as of September 2025. Working capital of CN¥-122.22 Million (current assets of CN¥1.92 Billion minus current liabilities of CN¥2.04 Billion) is measured against net assets of CN¥2.60 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Jinhe Biotechnology Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jinhe Biotechnology Co Ltd Working Capital to Net Assets (2008–2024)
This chart shows how Jinhe Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at -4.7%, reflecting working capital of CN¥-122.22 Million against net assets of CN¥2.60 Billion CNY. See 002688 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Jinhe Biotechnology Co Ltd (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jinhe Biotechnology Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002688 market cap.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 6.4% | CN¥159.49 Million | CN¥2.50 Billion | CN¥2.02 Billion | CN¥1.86 Billion | ▲ +15.0 pp |
| 2023 | -8.7% | CN¥-217.74 Million | CN¥2.52 Billion | CN¥2.04 Billion | CN¥2.26 Billion | ▼ -12.0 pp |
| 2022 | 3.4% | CN¥81.88 Million | CN¥2.43 Billion | CN¥1.75 Billion | CN¥1.66 Billion | ▼ -14.7 pp |
| 2021 | 18.0% | CN¥486.27 Million | CN¥2.70 Billion | CN¥1.65 Billion | CN¥1.16 Billion | ▲ +25.6 pp |
| 2020 | -7.6% | CN¥-132.91 Million | CN¥1.75 Billion | CN¥1.24 Billion | CN¥1.37 Billion | ▼ -12.9 pp |
| 2019 | 5.3% | CN¥95.37 Million | CN¥1.81 Billion | CN¥1.24 Billion | CN¥1.15 Billion | ▼ -6.7 pp |
| 2018 | 12.0% | CN¥212.81 Million | CN¥1.78 Billion | CN¥1.32 Billion | CN¥1.10 Billion | ▼ -1.8 pp |
| 2017 | 13.8% | CN¥225.18 Million | CN¥1.64 Billion | CN¥1.08 Billion | CN¥855.12 Million | ▼ -7.5 pp |
| 2016 | 21.2% | CN¥336.15 Million | CN¥1.58 Billion | CN¥865.20 Million | CN¥529.05 Million | ▲ +22.2 pp |
| 2015 | -1.0% | CN¥-10.05 Million | CN¥1.05 Billion | CN¥801.94 Million | CN¥811.99 Million | ▼ -57.3 pp |
| 2014 | 56.4% | CN¥538.86 Million | CN¥956.13 Million | CN¥764.88 Million | CN¥226.02 Million | ▲ +3.6 pp |
| 2013 | 52.8% | CN¥475.13 Million | CN¥900.07 Million | CN¥575.23 Million | CN¥100.10 Million | ▼ -10.6 pp |
| 2012 | 63.4% | CN¥547.54 Million | CN¥863.55 Million | CN¥669.89 Million | CN¥122.36 Million | ▲ +60.5 pp |
| 2011 | 2.9% | CN¥9.79 Million | CN¥334.40 Million | CN¥324.95 Million | CN¥315.16 Million | ▲ +16.2 pp |
| 2010 | -13.3% | CN¥-33.80 Million | CN¥254.83 Million | CN¥272.60 Million | CN¥306.40 Million | ▲ +38.7 pp |
| 2009 | -51.9% | CN¥-101.80 Million | CN¥196.03 Million | CN¥304.87 Million | CN¥406.67 Million | ▲ +16.7 pp |
| 2008 | -68.6% | CN¥-122.05 Million | CN¥177.82 Million | CN¥249.85 Million | CN¥371.90 Million | — |